3.50
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SCYNEXIS
From its filings with the US Securities and Exchange Commission
SCYNEXIS is based in Jersey City, New Jersey. Its shares trade on Nasdaq under the ticker SCYX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $20.6m and a net loss of $8.6m. At that date it held total assets of $59.0m and shareholders' equity of $49.4m. By business, License and Service [Member] brought in 93.0% of revenue, followed by Product [Member] at 7.0%.
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and most common mucorales species.
Ibrexafungerp is the first representative of this novel class of antifungals and was approved by the U.S. Food and Drug Administration (FDA) as BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC) in 2021 and 2022, respectively. Ibrexafungerp was licensed to GSK in May 2023.
A second generation fungerp SCY-247 is currently being evaluated in clinical trials and additional compounds from our proprietary fungerp platform, targeted to address significant unmet needs, are in earlier stages of development. The FDA has granted Qualified Infectious Disease Product status and Fast Track designations for the oral formulation of SCY-247 which would provide regulatory exclusivity of at least 10 years following commercial launch, if approved.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 May 2014
- Employees
- 27
- Website
- scynexis.com ↗
- Head office
- 1 EVERTRUST PLAZA, JERSEY CITY, NJ, 07302-6548
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Guy MacdonaldNon-Executive Independent Chairman of the Board$161,470
- Dr. David AnguloPresident, Chief Executive Officer, Director, since 2015$2.0m
- Mr. Ivor MacleodChief Financial Officer$1.2m
- Mr. Scott SukenickChief Legal Officer, General Counsel$1.2m
- Mr. Armando AnidoIndependent Director$131,470
- Dr. Steven GilmanIndependent Director$138,970
- Dr. Ann HanhamIndependent Director$138,970
- Mr. David HastingsIndependent Director$138,970
- Mr. Philippe TinmouthIndependent Director$128,970
- Ms. Irina KofflerInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Research Capabilities: SCYNEXIS Inc possesses a strong R&D team and cutting-edge technologies, allowing them to develop novel pharmaceutical products.
- Solid Financial Position: The company enjoys a healthy financial state, with sufficient reserves to support its ongoing operations and potential growth opportunities.
- Diverse Product Portfolio: SCYNEXIS Inc has a wide range of product offerings, spanning different therapeutic areas, which reduces dependency on a single product.
Weaknesses
- Dependency on Key Partners: SCYNEXIS Inc relies heavily on strategic partnerships for product development and commercialization, which exposes them to potential risks if these relationships falter.
- Limited Market Presence: The company faces stiff competition from established pharmaceutical giants, which may limit its market reach and customer base.
- Regulatory Challenges: SCYNEXIS Inc operates in a highly regulated industry. Compliance with strict regulatory standards and obtaining necessary approvals can be time-consuming and expensive.
Opportunities
- Market Expansion: SCYNEXIS Inc can explore new markets globally, expanding its presence beyond its current geographical footprint and tapping into untapped customer segments.
- Technological Advancements: Advancements in technology, such as artificial intelligence and genomic research, present opportunities for SCYNEXIS Inc to enhance their drug discovery and development processes.
- Increasing Healthcare Spending: With rising healthcare expenditures worldwide, the demand for innovative and effective pharmaceutical products is expected to grow, providing an opportunity for SCYNEXIS Inc to capture a larger market share.
Threats
- Intense Competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share. SCYNEXIS Inc faces the risk of being outperformed or overshadowed by larger competitors.
- Patent Expirations: The expiration of patents for existing drugs can lead to generic competition, potentially impacting sales and market share for SCYNEXIS Inc.
- Economic Volatility: Economic downturns and fluctuations can adversely affect overall healthcare spending, leading to reduced demand for pharmaceutical products and impacting the company's revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.